Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 750
Single User License Price INR 53925
Corporate User License Price USD 2250
Corporate User License Price INR 161775
Site License Price USD 1500
Site License Price INR 107850
Request a Quote

Report Title

Glaukos Corp (GKOS) - Product Pipeline Analysis, 2018 Update

Quote Request for License Type
License Type Price  
Single User License USD 750
Site License USD 1500
Enterprise Wide License USD 2250
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Glaukos Corp (GKOS) - Product Pipeline Analysis, 2018 Update


Quote Request for License Type
License Type Price  
Single User License USD 750
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Glaukos Corp (GKOS) - Product Pipeline Analysis, 2018 Update

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Glaukos Corp (GKOS) - Product Pipeline Analysis, 2018 Update



Executive Summary

Summary

Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as microstent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- tomoderate open-angle glaucoma. Glaukos' iStent is used in conjunction with cataract surgery. Glauko's iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm's canal. The company markets its products through a network of distributors in Germany, Italy, Canada, Portugal, Spain, the UK and France, among others. Glaukos is headquartered in San Clemente, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Glaukos Corp

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Glaukos Corp Company Overview 6

Glaukos Corp Company Snapshot 6

Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview 6

Glaukos Corp - Pipeline Analysis Overview 8

Glaukos Corp - Key Facts 8

Glaukos Corp - Major Products and Services 9

Glaukos Corp Pipeline Products by Development Stage 10

Glaukos Corp Ongoing Clinical Trials by Trial Status 12

Glaukos Corp Pipeline Products Overview 15

GTS400 15

GTS400 Product Overview 15

iDose Travoprost Intraocular Implant 16

iDose Travoprost Intraocular Implant Product Overview 16

iDose Travoprost Intraocular Implant Clinical Trial 17

IOP Sensor System 18

IOP Sensor System Product Overview 18

iStent Infinite 19

iStent Infinite Product Overview 19

iStent Infinite Clinical Trial 20

iStent inject Trabecular Micro-Bypass Stent 21

iStent inject Trabecular Micro-Bypass Stent Product Overview 21

iStent inject Trabecular Micro-Bypass Stent Clinical Trial 22

iStent SA 25

iStent SA Product Overview 25

iStent SA Clinical Trial 26

iStent Supra Suprachoroidal Micro-Bypass Stent 30

iStent Supra Suprachoroidal Micro-Bypass Stent Product Overview 30

iStent Supra Suprachoroidal Micro-Bypass Stent Clinical Trial 31

Glaukos Corp - Key Competitors 34

Glaukos Corp - Key Employees 35

Glaukos Corp - Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Glaukos Corp, Recent Developments 37

Jun 25, 2018: Glaukos' iStent inject micro-bypass device gets FDA approval 37

May 09, 2018: Glaukos Announces First Quarter 2018 Financial Results 37

Apr 14, 2018: IDE Pivotal Trial Results for Glaukos iStent inject Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery 38

Apr 11, 2018: Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive Surgery 39

Feb 28, 2018: Glaukos Reports Fourth Quarter and Full Year 2017 Financial Results 41

Feb 28, 2018: Raysearch Laboratories: First clinic now live with RayCare 42

Feb 27, 2018: Glaukos Technologies Featured in Numerous Presentations at 2018 American Glaucoma Society Meeting 43

Feb 27, 2018: International Study Shows Long-Term Titrated IOP Control with 1, 2 or 3 Glaukos iStent Trabecular Micro-Bypass Stents in Open-Angle Glaucoma Patients 44

Feb 26, 2018: Apollo Endosurgery Announces First ORBERA U.S. Post-Approval Publication 45

Feb 08, 2018: Glaukos iStent Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma, According to New Study 46

Appendix 48

Methodology 48

About GlobalData 51

Contact Us 51

Disclaimer 51

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Glaukos Corp Pipeline Products by Equipment Type 7

Glaukos Corp Pipeline Products by Development Stage 10

Glaukos Corp Ongoing Clinical Trials by Trial Status 12

List of Tables

Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview 6

Glaukos Corp Pipeline Products by Equipment Type 7

Glaukos Corp Pipeline Products by Indication 7

Glaukos Corp Ongoing Clinical Trials by Trial Status 7

Glaukos Corp, Key Facts 8

Glaukos Corp, Major Products and Services 9

Glaukos Corp Number of Pipeline Products by Development Stage 10

Glaukos Corp Pipeline Products Summary by Development Stage 11

Glaukos Corp Ongoing Clinical Trials by Trial Status 12

Glaukos Corp Ongoing Clinical Trials Summary 13

GTS400 - Product Status 15

GTS400 - Product Description 15

iDose Travoprost Intraocular Implant - Product Status 16

iDose Travoprost Intraocular Implant - Product Description 16

iDose Travoprost Intraocular Implant - A Prospective, Randomized, Phase III IND Study of iDose Travoprost in Open-angle Glaucoma Patients 17

iDose Travoprost Intraocular Implant - Assessment of iDose Delivery System's Safety and Preliminary Efficacy for the Reduction of Elevated Intraocular Pressure 17

IOP Sensor System - Product Status 18

IOP Sensor System - Product Description 18

iStent Infinite - Product Status 19

iStent Infinite - Product Description 19

iStent Infinite - A Prospective, Multi-center, Single-arm Clinical Study to Evaluate the Safety and Efficacy of iStent Infinite in Refractory Glaucoma Patients 20

iStent inject Trabecular Micro-Bypass Stent - Product Status 21

iStent inject Trabecular Micro-Bypass Stent - Product Description 21

iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent 22

iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects with Cataract Treated with Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent 22

iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of the Second Generation iStent Inject in Open-angle Glaucoma Subjects on Two Preoperative Topical Ocular Hypotensive Medications 23

iStent inject Trabecular Micro-Bypass Stent - A Prospective, Randomized Evaluation of Subjects with Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naive to Medical and Surgical Therapy, Treated with Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% 23

iStent inject Trabecular Micro-Bypass Stent - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction with Cataract Surgery 24

iStent inject Trabecular Micro-Bypass Stent - A Randomized Controlled Trial of Cataract Surgery Versus Combined Cataract Surgery with Insertion of iStent Inject 24

iStent SA - Product Status 25

iStent SA - Product Description 25

iStent SA - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg 23.B 26

iStent SA - A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject) 26

iStent SA - A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin 27

iStent SA - Initial Phase of U.S. IDE Clinical Trial for Standalone Version of iStent inject 27

iStent SA - The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients with Glaucoma or Ocular Hypertension: An Observational Study 28

iStent SA - Trabeculectomy with MMC and I Stent in Uveitic Glaucoma and POAG : Outcomes and Prognostic Factors 28

iStent SA - US Investigational Device Exemption (IDE) Pivotal Study of iStent SA Standalone Micro-Invasive Glaucoma Surgery 29

iStent Supra Suprachoroidal Micro-Bypass Stent - Product Status 30

iStent Supra Suprachoroidal Micro-Bypass Stent - Product Description 30

iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg 23.B 31

iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent 31

iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects with Cataract Treated with Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent 32

iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent 32

iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects with One Prior Trabeculectomy Treated Concurrently with One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin 33

iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction with Cataract Surgery 33

Glaukos Corp, Key Employees 35

Glaukos Corp, Subsidiaries 36

Glossary 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

STAAR Surgical Company

IRIDEX Corporation (US)

Cyberonics Inc

Glaukos Corp, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand